RT @AntiviralsRule: Remdesivir (=GS-5734) inhibits different zoonotic coronaviruses, also in early therapeutic setting (animal models). It…
RT @timothysheahan: Our timely new pub on a broad-spectrum antiviral for emerging coronavirus. Took a village @DenisonLab @Baric_Lab @Sarah…
Experimental drug Remdesivir (RDV) may be more promising. In study of mice with MERS - another #coronavirus - RDV showed clinical improvement in lung pathology & lower viral load. But lopinavir/ritonavir did not ⬇️ virus or improve lung pathology. (2/2
RT @NatureComms: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV…
Meldung/latest News auf https://t.co/WWDdPDdTWw
@maxpfiff Haben Sie einen Link zu einer Studie? Hier wird von Mausmodell und in-vitro Experimenten berichtet: https://t.co/grFUQWzyYm
RT @NIAIDNews: NEWS: NIAID-funded #MERS #coronavirus study in mice shows promise of anti-viral drug #remdesivir as treatment; NIAID scienti…
RT @a_chtung: вот статья о том, что в эксперименте на мышках с MERS-CoV ремдесивир+интерферон в профилактическом режиме (_якобы_) лучше, че…
@headmelted @DrEricDing I’m not sure I found the podcast on Tim Sheehan’s feed and also this paper he published https://t.co/DB8kyCWI9N
RT @Baric_Lab: Check out our latest work led by @timothysheahan on anti-viral treatment of MERS-CoV infection. Great collaborative project…
RT @NIAIDNews: NEWS: NIAID-funded #MERS #coronavirus study in mice shows promise of anti-viral drug #remdesivir as treatment; NIAID scienti…
Remdesevir antiviral drug shown promising therapeutic effect to prevent lung damage from #COVID19 coronavirus. https://t.co/MbmweCxlNh
Promising treatment for #Coronavius by @nature. Improved survival, reduced pathology and decreased viral load of the #2019nC0V. Further studies required, but much needed hope. https://t.co/8IOUFExuZk
@greg_folkers from here: https://t.co/u6j1gl880u
RT @timothysheahan: Our timely new pub on a broad-spectrum antiviral for emerging coronavirus. Took a village @DenisonLab @Baric_Lab @Sarah…
RT @a_chtung: вот статья о том, что в эксперименте на мышках с MERS-CoV ремдесивир+интерферон в профилактическом режиме (_якобы_) лучше, че…
вот статья о том, что в эксперименте на мышках с MERS-CoV ремдесивир+интерферон в профилактическом режиме (_якобы_) лучше, чем ингибиторы протеазы ВИЧ+интерферон. https://t.co/u6j1glpJp4
@nwtSwaps4CL @BlacklionCTA @LukeGromen @Convertbond This study does not give much reason for hope: https://t.co/AWoMJGkQOt
@trader_critical @biancoresearch You appear to be implying that he recovered within one day DUE to the drug. That's crazy. And it's exactly why a double blind placebo controlled study is being conducted currently. You should read this study before jumping
RT @a_chtung: Эффективность различных лекарственных средств в отношении экспериментальной MERS-CoV инфекции у мышей: https://t.co/bUa2VSbIfC
Эффективность различных лекарственных средств в отношении экспериментальной MERS-CoV инфекции у мышей: https://t.co/bUa2VSbIfC
@JonathanKBall @stuartjdneil @VikiLovesFACS Better than Pi's in vitro and in mice... https://t.co/dbBHscQGPH
RT @AndrewPaviaMD: Encouraging results for remdesivir (if you are a mouse with MERS) but unimpressive results for LPV/RTV +IFN. #2019nCoV #…
RT @timothysheahan: Our timely new pub on a broad-spectrum antiviral for emerging coronavirus. Took a village @DenisonLab @Baric_Lab @Sarah…
Remdesivir significantly decreased Middle East respiratory syndrome (MERS)-coronavirus lung viral loads and improved respiratory function and disease outcomes, whereas lopinavir/ritonavir plus IFN-beta only improved respiratory function https://t.co/9JZ7Vs
RT @mariagoneviral: While you're here, check out some of our work if you're interested! https://t.co/fDGBHqZNZn https://t.co/73WK7fEYQO ht…
RT @InfectiousDz: @Laurie_Garrett But not without precedent. There was an RCT using kaletra for MERS well before nCoV started w/some hopefu…
@Laurie_Garrett But not without precedent. There was an RCT using kaletra for MERS well before nCoV started w/some hopeful initial studies, which even Fauci has cited. https://t.co/JDjgGdSGIL https://t.co/AukjYJ6IDB https://t.co/nuFruFpPLT https://t.co/G7Q
RT @timothysheahan: Our timely new pub on a broad-spectrum antiviral for emerging coronavirus. Took a village @DenisonLab @Baric_Lab @Sarah…
Results RDV and IFNb have superior antiviral activity to LPV and RTV https://t.co/nMzS9lgSFw
@egretimemur `Lab ortaminda, human culture degil` noktasinda da bu makaleyi* (MERS) goz onune alirsak asi bulunana dek bununla idare etmek mumkun mudur? * https://t.co/5shch9T6pV
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV | Nature Communications https://t.co/mXupagJaSo
RT @IlindelatorreMD: Un registro de ensayos clínicos chinos cita al menos un estudio planificado. https://t.co/b9ibrZOZVh
RT @IlindelatorreMD: Un registro de ensayos clínicos chinos cita al menos un estudio planificado. https://t.co/b9ibrZOZVh
الفعالية العلاجية المقارنة للريديسيفير والجمع بين لوبينافير وريتونافير وبيتا الإنترفيرون ضد فيروس MERS كورونا https://t.co/hqlJfrxjhw
RT @IlindelatorreMD: Un registro de ensayos clínicos chinos cita al menos un estudio planificado. https://t.co/b9ibrZOZVh
RT @IlindelatorreMD: Un registro de ensayos clínicos chinos cita al menos un estudio planificado. https://t.co/b9ibrZOZVh
Un registro de ensayos clínicos chinos cita al menos un estudio planificado. https://t.co/b9ibrZOZVh
RT @CarlosdelRio7: In mice model remedesivir + INFb superior to LPV/r against MERS-CoV | @NatureComms https://t.co/QAnOCkNNOS
Article about $GILD drug Remdesivir being tested against MERS, showing improvement in acute lung injury and other params, etc...likely crossover to other bat CoVs. If even half true this is great they were already studying this, hopefully enough around.
RT @CarlosdelRio7: In mice model remedesivir + INFb superior to LPV/r against MERS-CoV | @NatureComms https://t.co/QAnOCkNNOS
RT @timothysheahan: Our timely new pub on a broad-spectrum antiviral for emerging coronavirus. Took a village @DenisonLab @Baric_Lab @Sarah…
RT @timothysheahan: Our timely new pub on a broad-spectrum antiviral for emerging coronavirus. Took a village @DenisonLab @Baric_Lab @Sarah…
RT @timothysheahan: Our timely new pub on a broad-spectrum antiviral for emerging coronavirus. Took a village @DenisonLab @Baric_Lab @Sarah…
RT @CEPIvaccines: While there are no approved treatments for MERS-CoV infection, a number of therapies are currently being evaluated💊 A re…
RT @timothysheahan: Our timely new pub on a broad-spectrum antiviral for emerging coronavirus. Took a village @DenisonLab @Baric_Lab @Sarah…
RT @timothysheahan: Our timely new pub on a broad-spectrum antiviral for emerging coronavirus. Took a village @DenisonLab @Baric_Lab @Sarah…
Um unnötige Verdachtsfälle zu vermeiden, empfiehlt die WHO eine Grippe Impfung.
RT @Navy_Mavy: https://t.co/jtljzqG0lm Erstmals kamen Coronaviren 2012 in Saudi Arabien vor. #Kamele waren Träger der Coronaviren. Weltweit…
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV https://t.co/ai3Pc5XCBj
RT @thisisashima: Also full genome availability = easier detection (good). Cause acute respiratory distress syndrome esp in older populatio…
RT @timothysheahan: Our timely new pub on a broad-spectrum antiviral for emerging coronavirus. Took a village @DenisonLab @Baric_Lab @Sarah…
RT @timothysheahan: Our timely new pub on a broad-spectrum antiviral for emerging coronavirus. Took a village @DenisonLab @Baric_Lab @Sarah…
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV https://t.co/hxwD9HfsPb
レムデシビル (RTV) の背景はこれだな。MARSに対するインターフェロン1bとの併用 (RTV-IFNb)は、感染の予防効果はないが、症状の改善に有効だったと😌 https://t.co/ogAj5OtZyb
Also full genome availability = easier detection (good). Cause acute respiratory distress syndrome esp in older population. Antivirals? Not yet but meds for older coronaviruses might be a good place to start (https://t.co/rroUdUopIh) (3/n)
RT @timothysheahan: Our timely new pub on a broad-spectrum antiviral for emerging coronavirus. Took a village @DenisonLab @Baric_Lab @Sarah…
RT @timothysheahan: Our timely new pub on a broad-spectrum antiviral for emerging coronavirus. Took a village @DenisonLab @Baric_Lab @Sarah…
@AyasunRuth it was found to be effective against SARS, MERS and other CoVs in vitro and in animal models. 1) https://t.co/YGvQskkwin 2) https://t.co/MIEID8bXLx 3) https://t.co/zyHldEzCPA
RT @VirusWhisperer: Very nice & independent corroboration of Chinese reports that type I IFN SPRAY prophylaxis might be effective and some…
RT @VirusWhisperer: Very nice & independent corroboration of Chinese reports that type I IFN SPRAY prophylaxis might be effective and some…
RT @CEPIvaccines: While there are no approved treatments for MERS-CoV infection, a number of therapies are currently being evaluated💊 A re…
RT @CEPIvaccines: While there are no approved treatments for MERS-CoV infection, a number of therapies are currently being evaluated💊 A re…
RT @CEPIvaccines: While there are no approved treatments for MERS-CoV infection, a number of therapies are currently being evaluated💊 A re…
RT @Nanyingih: MERS-CoV : Comparative therapeutic efficacy of antiviral combinations and interferon beta In vivo, Both prophylactic and th…
Price & availability...
RT @CEPIvaccines: While there are no approved treatments for MERS-CoV infection, a number of therapies are currently being evaluated💊 A re…
MERS-CoV : Comparative therapeutic efficacy of antiviral combinations and interferon beta In vivo, Both prophylactic and therapeutic remdesivir (RDV) improve pulmonary function and reduce lung viral loads and severe lung pathology. https://t.co/zUrUQxuh
RT @CEPIvaccines: While there are no approved treatments for MERS-CoV infection, a number of therapies are currently being evaluated💊 A re…
RT @CEPIvaccines: While there are no approved treatments for MERS-CoV infection, a number of therapies are currently being evaluated💊 A re…
RT @CEPIvaccines: While there are no approved treatments for MERS-CoV infection, a number of therapies are currently being evaluated💊 A re…
RT @CEPIvaccines: While there are no approved treatments for MERS-CoV infection, a number of therapies are currently being evaluated💊 A re…
While there are no approved treatments for MERS-CoV infection, a number of therapies are currently being evaluated💊 A recent @nature paper looks at the efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta👉https://t.co/6boY1rtFH
RT @CarlosdelRio7: In mice model remedesivir + INFb superior to LPV/r against MERS-CoV | @NatureComms https://t.co/QAnOCkNNOS
RT @mariagoneviral: While you're here, check out some of our work if you're interested! https://t.co/fDGBHqZNZn https://t.co/73WK7fEYQO ht…
RT @CarlosdelRio7: In mice model remedesivir + INFb superior to LPV/r against MERS-CoV | @NatureComms https://t.co/QAnOCkNNOS
RT @doctorsoumya: Clinical trials need to be done to test various potential therapeutics. Some clues from drugs tested on other #coronarvir…
RT @mariagoneviral: @SonyaBuyting And some other recent work from our team that might be of interest: https://t.co/adShMU3Jf2 https://t.co…
RT @CarlosdelRio7: In mice model remedesivir + INFb superior to LPV/r against MERS-CoV | @NatureComms https://t.co/QAnOCkNNOS
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. - PubMed - NCBI https://t.co/URxIj3NMdk
In mice model remedesivir + INFb superior to LPV/r against MERS-CoV | @NatureComms https://t.co/QAnOCkNNOS
RT @doctorsoumya: Clinical trials need to be done to test various potential therapeutics. Some clues from drugs tested on other #coronarvir…
RT @AndrewPaviaMD: Encouraging results for remdesivir (if you are a mouse with MERS) but unimpressive results for LPV/RTV +IFN. #2019nCoV #…
RT @AndrewPaviaMD: Encouraging results for remdesivir (if you are a mouse with MERS) but unimpressive results for LPV/RTV +IFN. #2019nCoV #…
RT @AndrewPaviaMD: Encouraging results for remdesivir (if you are a mouse with MERS) but unimpressive results for LPV/RTV +IFN. #2019nCoV #…
RT @AndrewPaviaMD: Encouraging results for remdesivir (if you are a mouse with MERS) but unimpressive results for LPV/RTV +IFN. #2019nCoV #…
RT @AndrewPaviaMD: Encouraging results for remdesivir (if you are a mouse with MERS) but unimpressive results for LPV/RTV +IFN. #2019nCoV #…
RT @AndrewPaviaMD: Encouraging results for remdesivir (if you are a mouse with MERS) but unimpressive results for LPV/RTV +IFN. #2019nCoV #…
RT @mariagoneviral: While you're here, check out some of our work if you're interested! https://t.co/fDGBHqZNZn https://t.co/73WK7fEYQO ht…
RT @doctorsoumya: Clinical trials need to be done to test various potential therapeutics. Some clues from drugs tested on other #coronarvir…
RT @mariagoneviral: While you're here, check out some of our work if you're interested! https://t.co/fDGBHqZNZn https://t.co/73WK7fEYQO ht…
Encouraging results for remdesivir (if you are a mouse with MERS) but unimpressive results for LPV/RTV +IFN. #2019nCoV #IDTwitter. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against… https://t.c
RT @doctorsoumya: Clinical trials need to be done to test various potential therapeutics. Some clues from drugs tested on other #coronarvir…
@anonymous_leeks Here's the best resource to check out the effect https://t.co/adShMU3Jf2 The window for treatment in viral respiratory disease is certainly early but how early can vary based on the pathogen itself.